177Lu-DOTA-TLX591

BIOLOGICAL2 trials

Sponsors

Telix Pharmaceuticals (Innovations) Pty Limited

Conditions

Metastatic Prostate CancerProstate Cancer

Phase 1

177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study

CompletedNCT04786847

Telix Pharmaceuticals (Innovations) Pty LimitedMetastatic Prostate Cancer

Start: 2022-01-30End: 2023-09-30Updated: 2024-02-12

Phase 2

External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)

CompletedNCT05146973

Telix Pharmaceuticals (Innovations) Pty LimitedProstate Cancer

Start: 2022-08-30End: 2024-03-24Updated: 2024-12-19

Related Papers

Theranostic Potential of 177Lu-TLX591 with Best Standard-of-Care and 68Ga-PSMA-11 PET for Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the Phase 1 ProstACT SELECT Trial

Cancers2026-07-20

Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes

Molecular Diagnosis & Therapy2024-03-0612 citations

Safety, tolerability, and dosimetry of <sup>177</sup>Lu-TLX591 with best standard of care in patients with PSMA-expressing metastatic castration-resistant prostate cancer (ProstAct-SELECT).

Journal of Clinical Oncology2024-01-29

177Lu-DOTA-TLX591 safety, biodistribution and dosimetry study (ProstACT-SELECT).

Journal of Clinical Oncology2022-06-016 citations